ETX0462
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ETX0462 is an experimental antibiotic drug which acts both as a β-lactamase inhibitor and also has separate antibiotic activity in its own right. It is active against a range of drug-resistant bacteria of concern including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. While ETX0462 is still in pre-clinical research and has not yet reached clinical trials, it was hailed as a significant advance as it represents an example of a completely new structural class of antibiotics, so even if this particular molecule does not get developed for medical use it is likely that related compounds will continue to be developed.
ETX0462 is an experimental antibiotic drug which acts both as a β-lactamase inhibitor and also has separate antibiotic activity in its own right. It is active against a range of drug-resistant bacteria of concern including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. While ETX0462 is still in pre-clinical research and has not yet reached clinical trials, it was hailed as a significant advance as it represents an example of a completely new structural class of antibiotics, so even if this particular molecule does not get developed for medical use it is likely that related compounds will continue to be developed.
See also
Avibactam Durlobactam Diazabicyclooctane β-lactamase inhibitor
Text derived from https://en.wikipedia.org/w/index.php?oldid=1363446960 under CC BY-SA 4.0; modifications have been made.